


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

1. (previously presented) A compound represented by formula I-1:



and the pharmaceutically acceptable salts and esters thereof wherein:

“a” is an integer selected from 1, 2 and 3; and b and c are each integers independently selected from 0, 1 and 2;

“A” represents a methylene or ethylene group;

each R^{1a} is independently selected from the group consisting of: -H, -F, -Cl, -Br, -C₁₋₆alkyl, -CN, -OH, -OC₁₋₆ alkyl, -fluoroC₁₋₆ alkyl, -fluoroC₁₋₆ alkoxy, -N(R^a)₂, -C₁₋₆alkylN(R^a)₂, -NHC(O)C₁₋₄alkyl, -C(O)NHC₁₋₄alkyl and -C(O)N(C₁₋₄alkyl)₂;

each R^{1b} is independently selected from the group consisting of: -H, -F, -C₁₋₆ alkyl, -OH, -OC₁₋₆ alkyl, -fluoroC₁₋₆alkyl, -fluoroC₁₋₆alkoxy, -N(R^a)₂ and -C₁₋₆alkylN(R^a), or one R^{1b} group can represent oxo and the other is as previously defined;

R¹ represents -H or is selected from the group consisting of:

a) halo, -OH, -CO₂R^a, -C(O)NR^aR^b, -N(R^a)₂, -S(O)₂NR^aR^b, -NO₂, -SO₂NR^bC(O)R^a, -NR^bSO₂R^a, -NR^bC(O)R^a, -C(O)SO₂NR^aR^b, -NR^bC(O)NR^aR^b, -NR^bCO₂R^a, -OC(O)NR^aR^b, -C(O)NR^bNR^aR^b, -CN, -S(O)_pR^a and -OSO₂R^a,

b) -C₁₋₁₀alkyl, -C₂₋₁₀alkenyl, -C₂₋₁₀alkynyl, -OC₁₋₁₀alkyl, -OC₃₋₁₀alkenyl and -OC₃₋₁₀alkynyl, said groups being optionally substituted with: -OH, -CO₂R^a, -C(O)NR^aR^b, -C(O)N(R^a)C₁₋₆alkenyl, -C(O)N(R^a)C₁₋₆alkynyl, -N(R^a)₂, -S(O)₂NR^aR^b, -SO₂NR^bC(O)R^a, -NR^bSO₂R^a, -NR^bC(O)R^a, -C(O)SO₂NR^aR^b, -NR^bC(O)NR^aR^b, -NR^bCO₂R^a, -OC(O)NR^aR^b, -C(O)NR^bNR^aR^b, -S(O)_pR^a, Aryl, and up to 5 fluoro groups;

c) Aryl optionally substituted with 1-2 members selected from the group consisting of: -F, -Cl, -Br, -C₁₋₆ alkyl, -C₃₋₆cycloalkyl, -CN, -OH, -OC₁₋₆ alkyl, -fluoroC₁₋₆ alkyl, -fluoroC₁₋₆alkoxy, -NH₂, -NHC₁₋₄alkyl, -N(C₁₋₄alkyl)₂, -C₁₋₆alkylNH₂, -C₁₋₆alkyl-NHC₁₋₄alkyl, -C₁₋₆alkylN(C₁₋₄alkyl)₂, -C₁₋₆alkyl-CN, -NHC(O)C₁₋₄alkyl, -C(O)NHC₁₋₄alkyl and -C(O)N(C₁₋₄alkyl)₂;

each p independently represents an integer selected from 0, 1 and 2;

R⁴ and R⁵ are each independently selected from the group consisting of -H, -C₁₋₆ alkyl, -OC₁₋₆alkyl, -OH, -fluoro, -fluoroC₁₋₆alkyl, -fluoroC₁₋₆alkoxy, -N(R^a)₂, and

CR⁴R⁵ can represent a group selected from carbonyl, thiocarbonyl, C=NR^a and a 3-7 membered cycloalkyl ring,

Y is quinolinyl;

each R^a is independently selected from the group consisting of -H and :


(a) -C₁₋₁₀alkyl, -C₃₋₆cycloalkyl, -C₃₋₁₀alkenyl, or -C₃₋₁₀alkynyl, optionally substituted with 1-3 fluoro groups or 1-2 members selected from the group consisting of: -OH, -OC₁₋₆alkyl, -CN, -NH₂, -NHC₁₋₄alkyl, and -N(C₁₋₄alkyl)₂;

(b) Aryl or Ar-C₁₋₆alkyl-, the aryl portions being optionally substituted with 1-2 of -C₁₋₆ alkyl, -CN, -OH, -OC₁₋₆ alkyl, -fluoroC₁₋₆ alkyl, -fluoroC₁₋₆ alkoxy, -C₁₋₆alkylNH₂, -C₁₋₆alkylNHC₁₋₄alkyl, -C₁₋₆alkylN(C₁₋₄alkyl)₂, -NH₂, -NHC₁₋₄alkyl, -N(C₁₋₄alkyl)₂, -NHC(O)C₁₋₄alkyl, -C(O)NHC₁₋₄alkyl, -C(O)N(C₁₋₄alkyl)₂, -CO₂H and -CO₂C₁₋₆alkyl groups, and 1-3 -F, -Cl or -Br groups; and the alkyl portion of Ar-C₁₋₆alkyl- being optionally substituted with -OH, -OC₁₋₆alkyl, -NH₂, -NHC₁₋₄alkyl, -N(C₁₋₄alkyl)₂, and 1-3 fluoro groups;

each R^b is independently selected from the group consisting of: -H, -NH₂, and -C₁₋₁₀alkyl optionally substituted with members selected from the group consisting of 1-3 fluoro groups and 1-2 of -OH, -OC₁₋₆alkyl, -NH₂, -NHC₁₋₄alkyl and -N(C₁₋₄alkyl)₂;

and when present in the same moiety, (a) R^a and R^b, (b) two R^a groups or (c) two R^b groups can be taken in combination with the atom or atoms to which they are attached and any intervening atoms and represent a 4-7 membered ring containing 0-3 heteroatoms selected from O, S(O)_p and N, and the 4-7 membered ring may be optionally substituted with a member selected from the group consisting of -C₁₋₆alkyl, -C₂₋₆acyl and oxo.


2. (previously presented) The compound of claim 1 of structural formula Ia-1:



and the pharmaceutically acceptable salts and esters thereof, wherein “a” is an integer selected from 1, 2 and 3; and b and c are each integers independently selected from 0, 1 and 2; provided that the sum of “a” + b + c is from 1 to 5.

3. **(canceled)**

4. **(previously presented)** The compound of claim 1 of structural formula Ib-1:



and the pharmaceutically acceptable salts and esters thereof wherein: “a” is an integer selected from 2 and 3; and b and c are integers independently selected from 0 and 1; provided that the sum of “a” + b + c is from 2 to 4.

5. **(original)** The compound of claim 4 wherein “a” is 2, and b and c are integers selected from 0 and 1.

6. **(canceled)**

7. **(previously presented)** The compound of claim 1 wherein of the three R^{1a} groups shown in the generic structural drawing of formula I-1, two R^{1a} groups represent -H and one R^{1a} group is selected from the group consisting of: -F, -Cl, -C₁₋₆ alkyl, -CN, -OC₁₋₆ alkyl, -fluoroC₁₋₆ alkyl, -fluoroC₁₋₆alkoxy, -N(R^a)₂, -C₁₋₆alkylN(R^a)₂, -NHC(O)C₁₋₄alkyl, -C(O)NHC₁₋₄alkyl and -C(O)N(C₁₋₄alkyl)₂.

8. **(canceled)**

9. **(previously presented)** The compound of claim 1 wherein both R^{1b} groups represent -H.

10. **(previously presented)** The compound of claim 1 wherein R¹ represents a member selected from the group consisting of:

a) -C(O)NR^aR^b, -N(R^a)₂, -S(O)₂NR^aR^b, -SO₂NR^bC(O)R^a, -NR^bSO₂R^a, -NR^bC(O)R^a, -CN, -S(O)_pR^a and -OSO₂R^a; and


b) -C₁₋₁₀alkyl, -C₃₋₆alkenyl, -C₃₋₆alkynyl, -OC₁₋₁₀alkyl, -OC₃₋₆alkenyl and -OC₃₋₁₀alkynyl, said groups being optionally substituted with a member selected from the group consisting of: -CO₂R^a, -C(O)NR^aR^b, -C(O)N(R^a)C₁₋₆alkenyl, -C(O)N(R^a)C₁₋₆alkynyl, -N(R^a)₂, -S(O)₂NR^aR^b, -SO₂NR^bC(O)R^a, -NR^bSO₂R^a, NR^bC(O)R^a, -S(O)_pR^a, Aryl, and up to 5 fluoro groups.

11 - 13. **(canceled)**

14. **(previously presented)** The compound of claim 1 wherein -(CR⁴R⁵)- represents -CH₂-.

15 - 20. **(canceled)**

21. **(previously presented)** The compound of claim 1 of structural formula Ic-1:



wherein R^4 and R^5 are both $-H$;

R^1 is selected from the group consisting of:

- a) $-OC(O)NR^aR^b$, and $-C(O)NR^aR^b$; and
- b) C_{1-3} alkyl substituted with a member selected from: $-C(O)-NR^aR^b$.

22 - 23. **(canceled)**

24. **(original)** A pharmaceutical composition comprised of a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

25. **(canceled)**

26. **(withdrawn)** A method for treating a leukotriene-mediated medical condition comprising administering a therapeutically effective amount of a compound of claim 1 to a patient in need of such treatment.

27 - 36 **(canceled)**